X

News

July 2014: ReveraGen Drug Will Move to Human Testing

ReveraGen BioPharma, based in Silver Spring, Md., is moving ahead with a phase 1 trial of an experimental compound in development to treat Duchenne muscular dystrophy, made possible by a $2 million grant from U.S.-based MDA and three United Kingdom-based DMD organizations. The drug, dubbed VBP15, will be evaluated for safety in healthy people in this phase 1 study.
More >